The indications for adjuvant therapy in resected oral tongue cancers are based on both clinical and pathological factors, with clear evidence for adjuvant radiation in patients with pathologically positive neck lymph nodes, positive margins, and extracapsular extension, but the data for patients with no nodal disease are sparse.
oral tongue have poorer outcomes when compared with similarly staged cancers of the oropharynx and larynx. [3] [4] [5] [6] An inferior survival may be due to inherently aggressive histologic characteristics predisposing the cancer to nodal spread to the contralateral neck, "skip metastases" in the ipsilateral neck, or other, unspecified reasons.
7-10
Initial surgical resection of oral cavity cancers is the current standard of care.
11 Elective neck dissection for clinically nodenegative (cN0) patients is recommended in early-stage oral tongue cancers, 12 but the need for adjuvant radiotherapy (RT) alone or radiation with combined chemotherapy (CRT) is gleaned from studies incorporating cancers of all head and neck subsites. [13] [14] [15] [16] There are few studies focusing explicitly on the oral tongue and even fewer addressing the subset of oral tongue cancer patients with negative lymph nodes, but generally the literature supports similar pathological risk factors, 9,17,18 in addition to depth of invasion, 10 as indications for adjuvant therapy. Because of sparse literature there is controversy about the role of adjuvant therapy in cN0 or pathologically node-negative (pN0) patients. The objectives of our study were to determine which patient, tumor, or treatment related factors were associated with worse disease control and survival for patients with cN0 and/or pN0 oral tongue cancers.
Methods

Patient Selection
With institutional review board-approval, the medical records of patients from 2003 to 2013 treated with initial total or partial glossectomy for oral tongue squamous cell carcinoma were reviewed. The tumors of all patients were staged prior to surgery with a computerized tomographic (CT) scan of the neck. We excluded patients with node-positive disease (cN positive and/or pN positive) as well as patients with lack of adjuvant treatment records. Staging was based on the 7th edition of the American Joint Committee on Cancer guidelines. 19 Chemoradiation was recommended for positive margins. Adjuvant RT alone was generally given for T3 or T4 disease, perineural invasion (PNI), extensive depth of invasion, and close margins of less than 5 mm. All patients were followed with periodic physical examination, including fiberoptic endoscopy when necessary, and surveillance CT imaging.
Statistical Analysis
All statistics were computed using SAS software (version 9.3; SAS Institute Inc). Patient characteristics examined were age, sex, and race. Based on the rising incidence of oral tongue cancers in patients 44 years or younger, [20] [21] [22] [23] [24] [25] age was divided into those older than 44 years and those 44 years or younger. Tumor characteristics examined included T stage, histological grade, PNI, lymphovascular space invasion (LVSI), margins (positive, negative, and close, defined as <5 mm), and depth of invasion. Depth of invasion was categorized into less than 3 mm or 3 mm or greater based on previous studies. 26 Treatment characteristics analyzed including use of elective neck dissection at time of definitive surgery and type of adjuvant therapy received (none, RT, or CRT). These characteristics were compared across LVSI groups using χ 2 tests or Fisher exact tests, where appropriate, for categorical variables, and analysis of variance for numeric variables. Local control (LC) was defined as absence of failure at the primary site. Locoregional control (LRC) was defined as absence of failure at the primary site or bilateral necks. Ultimate locoregional control (ULRC) was defined as absence of failure at the primary site or necks, taking into account salvage therapeutic attempts for failure. Overall survival (OS) was defined as time to death or time to last follow-up from diagnosis. Survival estimates for end points were estimated using the Kaplan-Meier product limit method, and survival distributions were compared using the log-rank test. 27 In addition, LC and LRC were defined as time from diagnosis to local failure and locoregional failure, respectively, for the purposes of estimating yearly actuarial rates. Two-and 3-year survival rates for each end point were reported. Univariable (UVA) logistic regression models for LC, LRC, and ULRC and Cox proportional hazard models for OS were fitted to the defined patient, tumor, and treatment characteristics. Multivariable (MVA) logistic regression and proportional hazard models were generated for these end points, using a backward selection with an α-level of removal of .20 based on the local Wald test P values for each variable. Owing to small event sizes in levels of several variables, Firth penalized maximum-likelihood estimation 28 was applied for the UVA analysis of ULRC to reduce bias in the 95% CIs and parameter estimates. Separate Kaplan-Meier survival estimates were performed comparing patients with and without LVSI for each end point. The proportional hazards assumption was checked for all survival models. Significance was assessed at the P=.05 level. Graphics were created using R software (version 2.15.1; R Foundation).
Results
Patient Characteristics
After review of 245 patient medical records, 180 patients met study inclusion criteria; 102 patients (56.7%) were female and 42 patients (23.3%) were younger than 45 years at diagnosis.
Key Points
Question What is the impact on disease control and overall survival of lymphovascular space invasion (LVSI) on pathologic findings for patients with node-negative oral tongue cancers treated with upfront definitive surgical resection?
Findings In this study of 180 consecutive patients treated with standard of care therapy, LVSI was associated with worse local control, locoregional control, and overall survival.
Meaning
In node-negative oral tongue cancers, LVSI on pathologic findings should warrant consideration of more aggressive adjuvant therapy, which should be further investigated in a prospective setting.
Fifty-five patients were excluded because of clinically (45 patients) or pathologically (10 patients) proven nodal disease found during elective neck dissection. Ten patients were excluded owing to transfer of care to an outside facility after surgery. The patient, tumor, and treatment characteristics of our study population are summarized in Table 1 . A total of 153 patients (62%) had preoperative positron emission tomographic-CT staging. Median follow-up time was 4.9 years (range, 0.9-12.5 years were associated with improved LRC ( Table 2 ). There was a nonsignificant finding for depth of invasion of at least 3 mm (OR, 0.41; 95% CI, 0.14-1.18; P = .10) and PNI (OR, 0.41; 95% CI, 0.15-1.15; P = .10) for worse LRC. The 2-and 3-year LRC rates were 75.2% (95% CI, 68.2%-80.9%) and 72.7% (95% CI, 65.5%-78.7%), respectively. The sites of regional failure were as follows: 41 in the ipsilateral neck, 3 in the contralateral neck, and 3 in other oral cavity subsites.
Salvage Therapy and Ultimate Locoregional Control
Salvage surgery was attempted in 42 patients for failure at the primary site, with durable control achieved in 30 patients. Adjuvant RT was added in 8 patients, and adjuvant CRT was added in 11 patients. Salvage surgery was attempted in 33 patients who had neck failures, with durable control achieved in 22 patients. Adjuvant RT was added in 9 patients and adjuvant CRT in 15 patients. Of these cases, 12 were reirradiation. Overall, at the time of last follow-up the ULRC rate was 83.3%. On UVA, African American race (OR, 0.04; 95% CI, 0.01-0.95; P = .04), LVSI (OR, 0.28; 95% CI, 0.12-0.65; P < .01), and close margins (OR, 0.30; 95% CI, 0.13-0.69; P < .01) were associated with worse ULRC (eTable 4 in the Supplement). On MVA, LVSI (OR, 0.22; 95% CI, 0.08-0.59; P < .01) and close margins (OR, 0.24; 95% CI, 0.09-0.62; P < .01) were associated with worse ULRC, with lack of upfront neck dissection showing a nonsignificant finding of worse ULRC (OR, 2.25; 95% CI, 0.89-5.68; P = .09) ( Table 3) .
Overall Survival
On UVA, age greater than 44 years (hazard ratio [HR], 6.15; 95% CI, 1.92-19.68; P < .01), depth of invasion greater than 3 mm (HR, 1.98; 95% CI, 1.01-3.87; P = .04), LVSI (HR, 1.96; 95% CI, 1.10-3.47; P = .02), and close margins (HR, 1.78; 95% CI, 1.03-3.06; P = .04) were associated with worse OS (eTable 5 in the Supplement). On MVA, age older than 44 years (HR, 4.38; 95% CI, 1.34-14.27; P = .01) and LVSI (HR, 2.20; 95% CI, 1.19-4.06; P = .01) were associated with worse OS (Table 4) . There was a nonsignificant finding for depth of invasion of at least 3 mm (HR, 2.11; 95% CI, 0.99-4.51; P = .054) to be associated with worse OS. The 2-and 3-year overall survival rates were 94.4% (95% CI, 89.9%-97.0%) and 86.1% (95% CI, 79.9%-90.4%), respectively.
Impact of Lymphovascular Space Invasion
Given that LVSI was associated with worse outcomes as detailed herein, we wanted to more closely examine this cohort compared with the rest of the population. Twenty percent of the population (n = 36) had LVSI. No patients received adjuvant therapy for LVSI alone. Patients with and without LVSI were compared with a trend for more moderately differentiated patients (P = .05) and patients with depth of invasion of at least 3 mm (P = .07) having LVSI (eTable 6 in the Supplement). At 3 years, the LC was 87.0% ( 9 5 %C I ,8 0 .2 % -9 1 . 6 % )i np a t i e n t swi t h o u tL V S Iv s54 . 9 % (95% CI, 36.5%-70.0%) in patients with LVSI (log-rank P < .01) (Figure, A) . At 3 years, the LRC was 81.9% (95% CI, 74.4%-87.4%) in patients without LVSI vs 38.8% (95% CI, 22.8%-54.6%) in patients with LVSI (log-rank P < .01) (Figure, B) . At 3 years the OS rates were 90.3% (95% CI, 83.8%-94.3%) in patients without LVSI vs 71.3% (95% CI, 53.2%-83.4%) in patients with LVSI (log-rank P = .01) (Figure, C) . Overall, 5 patients developed distant metastasis, with only 1 patient with LVSI developing distant disease.
Toxic Effects
No patient died of treatment-related toxic effects. All patients were able to receive their full course of prescribed RT. Two patients treated with concurrent cisplatin missed 1 cycle; 1 for neutropenia and the other per patient preference. Three patients developed osteoradionecrosis of the mandible. Six patients had long-term percutaneous endoscopic gastrostomy tube dependence. 
Discussion
Our series serves as one of the largest in the literature specifically examining patients with node-negative oral tongue cancer treated with initial surgery. We demonstrated that the presence of pathological LVSI is associated with worse LC, LRC, and OS. To our knowledge, this study contains the largest number of patients with node-negative oral tongue cancer with LVSI. The LC, LRC, and OS rates of our series are in line with those of previously published reports.
3,5,9,17
The surgical treatment of oral tongue cancer is evolving. A recent randomized clinical trial 12 found a survival benefit to elective neck dissection in node-negative oral cavity cancers, but surveillance was poor, which threatened the validity of the conclusions. 29 In this series, 12 500 patients were randomized to upfront elective neck dissection vs neck dissection for nodal recurrence. At 3 years, those who underwent upfront neck dissection showed improvement in disease-free survival and OS. While this trial included other subsites of the oral cavity, over 85% were oral tongue primary tumors. Adjuvant radiation was delivered for positive nodes, depth of invasion greater than 1 cm, positive margin, or presence of certain risk factors (PNI, LVSI, high grade). On MVA, only depth of invasion was found to be predictive of node positivity. However, only 13% of these patients had PNI or LVSI, and the authors 12 did not report them separately, so specific conclusions about LVSI are difficult to make. In our series, we similarly found that use of elective neck dissection was associated with improved LRC (OR, 2.99; 95% CI, 1.16-7.73) but not OS. This suggests that even with appropriately delivered adjuvant therapy, the use of elective neck dissection is beneficial in node-negative oral tongue cancers. The standard indications for adjuvant therapy in oral tongue cancers have been derived from 2 large randomized trials (EORTC and RTOG). [13] [14] [15] [16] In both trials, cancers from several subsites were combined together, including the oral cavity, oropharynx, larynx, and hypopharynx. In the EORTC trial, patients with oral cavity or oropharynx primaries with nodal level IV or V disease, advanced T stage, PNI, and LVSI were included. In the RTOG trial, patients with 2 or more A, Local control, defined as the time from diagnosis to failure at the primary site or time to last follow-up, was analyzed among the patients who had pathological presence of LVSI (36 patients) and compared with those who did not (141 patients). Kaplan-Meier estimates for LC among these patients showed that 3-year LC is significantly worse with LVSI (54.9%) vs no LVSI (87.0%) (P < .01). B, Locoregional control, defined as the time from diagnosis to failure at primary site or in the neck or time to last follow-up, was analyzed among the patients who had pathological presence of LVSI (36 patients) and compared with those who did not (141 patients). Kaplan-Meier estimates for LRC among these patients showed that 3-year LRC is significantly worse with LVSI (38.8%) vs no LVSI (81.9%) (P < .01). C, Overall survival, defined as the time to death or time to last follow-up from diagnosis, was analyzed among the patients who had pathological presence of LVSI (36 patients) and compared with those who did not (141 patients). Kaplan-Meier estimates for OS among these patients showed that 3-year OS is significantly worse with LVSI (53.2%) vs no LVSI (83.8%) (P = .02). Plus sign indicates censored data. 17 This study included node-positive patients and examined only patients who were treated with postoperative RT. They determined that 5-year LRC rates were significantly worse in patients with PNI, ECE, and T3 or T4 disease. Diseasespecific survival was worse in patients with ECE or PNI. They did not find LVSI to be a significant predictor of control or survival. This study suggests that adjuvant RT may be sufficient for LVSI, but the inclusion of all oral cavity subsites, node-positive disease, as well as lack of depth of invasion information, makes the study difficult to directly apply to node-negative oral tongue cancers. Similarly, in a series of 88 patients with pathologically node-negative oral tongue cancers, PNI was found to be an independent predictor of nodal disease and extracapsular spread. 18 The largest series examining node-negative oral tongue cancers was a multiinstitutional review of 164 patients, none of whom received adjuvant therapy. 9 The authors 9 determined that only tumor thickness of 4 mm or greater was predictive of regional recurrence. While this series suggests that depth of invasion is an independent risk factor for recurrence, it is difficult to make conclusions about LVSI because only 5 patients in their series had this pathological feature.
Research Original Investigation
Limitations
Our series has several strengths and limitations. The major strength is the large number of patients, focusing on a specific clinical scenario: node-negative oral tongue cancers treated with modern therapy. We also have detailed information in regard to treatment type, outcome, and information on toxic effects. The major limitation of our series is the inherent bias of retrospective reviews, namely, the reliance on medical record for accurate information on follow-up. In addition, there is a selection bias with medical record review because there is no randomization of patients.
Conclusions
This series summarizes a large, single-institution experience in the management of clinically and/or pathologically nodenegative oral tongue cancer. LVSI seems to be associated with local and regional recurrence, worse survival, without an increase in distant metastasis. Given the locoregional recurrence risk in patients with node-negative oral tongue cancers treated with definitive surgery, the presence of LVSI warrants consideration of adjuvant radiation to the primary site and draining lymphatics, which ideally should be investigated in a prospective setting. 
